Chimeric antigen receptor (CAR) T-cell therapy achieves remission in 80–90% of children with relapsed or refractory acute lymphoblastic leukemia (ALL), but only 20% in pediatric patients with solid tumors. Identifying early biomarkers of response could allow timely interventions for non-responders and support the optimization of effective combination therapies. The spleen plays a central role in immune regulation and lymphocyte trafficking, potentially affecting CAR T-cell expansion, persistence, and toxicity risk. The purpose of our study was to explore if pre treatment spleen to liver SUV ratio (SLR) measured on 18FDG PET/MR may correlate with their treatment outcomes. Read More

Meeting name: SPR 2026 Annual Meeting , 2026

Authors: Vasyliv Iryna

Keywords: Immunotherapy, Outcomes, Hybrid Pet/MRI

Most pediatric patients with acute lymphoblastic leukemia (ALL) demonstrate tumor remission during the first weeks or months after Chimeric Antigen Receptor (CAR) T-cell therapy. However, 30–60% of patients ultimately relapse, highlighting the need for early, non-invasive risk stratification after treatment. 18FDG PET/MR can assess the bone marrow without biopsy, but its prognostic utility after CAR T-cell therapy remains unexplored. The purpose of the study was to determine if changes in bone marrow metabolic activity on 18F-FDG PET/MR at day 28 after CAR T-cell therapy is associated with five-year survival in children with ALL. Read More

Meeting name: SPR 2026 Annual Meeting , 2026

Authors: Vasyliv Iryna

Keywords: Hybrid Pet/MRI, Leukemia, Bone Marrow